A Safety and Efficacy Study of Alefacept in the Treatment of Moderate to Severe Erosive Mucosal Lichen Planus
Stopped early · Phase 2 · Has a placebo group
Conditions studied: Lichen Planus
In brief
The purpose of this study is to find out how safe and effective an investigational drug called alefacept (amevive) is for the treatment of moderate to severe erosive mucosal lichen planus. Lichen planus is a skin disease that can last a long time and cause significant pain, itching, and scarring. It can affect the mucous membranes (area inside the mouth and vagina) and these areas can become erosive (sores can develop). Currently there is no known cure for this disease. An investigational drug is one that has not been approved by the United States (US) Food and Drug Administration (FDA) to treat a particular condition or disease. Alefacept has been approved to treat psoriasis (a scaly skin rash). A number of reports suggest that lichen planus develops for some of the same reasons as psoriasis, but alefacept is not yet approved for the treatment of psoriasis.
Key facts
- Study ID
- NCT00135733
- Run by
- Massachusetts General Hospital
- People needed
- 13
- Starts
- 2004-04-01
- Expected to finish
- 2004-12-01
- Last updated by the study team
- 2009-02-12
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
Where it is running
- Clinical Unit for Research Trials in Skin — Boston, Massachusetts, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.